Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 20, 2011

View Archived Issues

Small-molecule inhibitors of ezrin developed to target bone cancer

U.S. study uncovers candidate SNPs associated with susceptibility to cold sores

Vertex Pharmaceuticals synthesizes novel products

Isis Pharmaceuticals expands pipeline

DSMB recommends continuation of VISTA-16 trial

Vernalis and Lundbeck collaboration reaches second milestone

Neovacs completes recruitment in phase II TNF-Kinoid trial

New inhibitor of cyclin-dependent kinase 9 shows preclinical potential in CLL

Chugai Pharmaceutical presents new MEK 1 inhibitor

Novel biomarker for B-cell lymphoma discovered in Japan

New prodrugs of a coagulation factor VIIa inhibitor designed by Eisai

Novel GPR52 receptor agonists disclosed by Takeda Pharmaceutical

U.K. team presents novel cyclophilin inhibitors

New chelating cyclopeptides prepared by French group

Impax advances IPX-159 to phase IIb testing

FDA clears assay to help predict prognosis of patients with heart failure

Millennium Pharmaceuticals patents new histone deacetylase 6 inhibitors

Sanofi sells Dermik

Rib-X Pharmaceuticals reports data from phase IIb delafloxacin study

NeurogesX gives update on Qutenza sNDA

Gilead Sciences submits sNDA for Truvada

StemCells completes treatment of first cohort in phase I/II spinal cord injury trial

Dicerna and Kyowa Hakko Kirin select DsiRNA candidate for development

ThromboGenics and BioInvent complete enrollment in phase IIb TB-402 study

FDA does not require REMS program for Korlym in Cushing's syndrome

Vertex gives update on Kalydeco NDA and MAA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...